Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK first quarter

This article was originally published in The Tan Sheet

Executive Summary

Pharma company's smoking cessation unit recovered from a disappointing fourth quarter 2003 and advanced 17% in the first quarter 2004 to drive Consumer Healthcare revenues up 6% to $1.3 bil. Boosted by NRT products, OTC medicine sales were ahead 2% to $627.3 mil. Analgesic sales rose 12%, helping to offset an 18% drop in dermatological product sales. Oral care sales increased 6% to $462 mil. based on strong performances of Aquafresh and Sensodyne. Nutritional healthcare grew 13% due to strong international and European growth. ...

You may also be interested in...



GSK Hopes To Energize Tagamet HB By Targeting New Male Audience

GlaxoSmithKline Consumer Healthcare is attempting to reinvigorate its OTC Tagamet heartburn remedy brand with a new marketing and advertising campaign targeting young males

US FDA Tech Modernization Plan’s Costs Uncertain

Agency officials determining needs using existing budgets before requesting more funds and will engage with tech investors for design advice.

ICER’s Biopharma Members: Why They Joined And What They Get

Biopharma’s funding support for the Institute for Clinical and Economic Review has been slightly above that of payers and providers for the past three to four years.

Topics

UsernamePublicRestriction

Register

PS096774

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel